Is MaxCyte, Inc. overvalued or undervalued?
As of March 22, 2022, MaxCyte, Inc. is considered overvalued and rated as risky due to poor financial metrics, including a Price to Book Value of 1.15, an EV to Sales ratio of 2.43, and a negative ROCE of -80.39%, despite performing better than some peers like Scholar Rock in terms of EV to EBITDA.
As of 22 March 2022, the valuation grade for MaxCyte, Inc. moved from does not qualify to risky. The company is currently considered overvalued based on its financial metrics and peer comparisons. Key ratios include a Price to Book Value of 1.15, an EV to Sales ratio of 2.43, and a ROCE of -80.39%. In comparison to peers, MaxCyte's EV to EBITDA stands at -2.00, while Scholar Rock Holding Corp. has a significantly worse EV to EBITDA of -9.8457, indicating that MaxCyte is not the worst performer in its category. However, the overall financial health remains concerning, especially with a YTD return of -47.84% compared to the S&P 500's 2.44%, reinforcing the notion that the stock is overvalued relative to its performance and industry standing.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
